---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Intravesical chemotherapy"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Intravesical chemotherapy. Topics: Guideline description: intravesical chemotherapy and chemotherapy combinations; Guideline description: device-assisted chemotherapy; Approval status: valrubicin approved, other intravesical chemotherapy used off-label; Valrubicin: labeled indication, dosing, and administration; 7 further topics. 11 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/intravesical-chemotherapy"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Intravesical chemotherapy

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Intravesical Chemotherapy

<a id="topic-2.2.2.1.2-1"></a>

### Guideline description: intravesical chemotherapy and chemotherapy combinations

> “Valrubicin, an anthracycline topoisomerase inhibitor that interferes with deoxyribonucleic acid (DNA) synthesis and metabolism by inhibiting the activity of DNA topoisomerase II, leading to cell cycle arrest in the G2 phase, was approved by the FDA in 1998, but its use has been limited due to the availability of more effective options”
> “have been assessed in a small series of BCG-recurrent NMIBC patients usually not fulfilling the definition of BCG-unresponsive, with inconsistent results.”
> “sequential intravesical administration of gemcitabine and docetaxel is an emerging treatment option in patients failing BCG.”
> “In a retrospective series of 102 patients with BCG-unresponsive NMIBC, with or without CIS, 6-, 12-, and 24-month HG RFS was 78%, 65% and 49%, respectively.”
> “Fifty-seven percent of patients experienced mild/moderate adverse effects, the most common being represented by urinary frequency/urgency (41%) and dysuria (21%) and leading to treatment delay in only 7% of cases”
> “Notably, published data on this combination are currently predominantly retrospective, with only one small prospective series reported in Table 7.4”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.2-2"></a>

### Guideline description: device-assisted chemotherapy

> “In a phase III RCT including predominantly high-risk NMIBC patients failing at least a previous induction course of BCG, MMC combined with microwave-induced hyperthermia (RITE) provided 35% overall DFS at two years as compared to 41% in the control arm (treated with either BCG, MMC or MMC and EDMA at the discretion of the investigator).”
> “A prospective phase II single-arm study evaluating the efficacy and safety of the EMDA-MMC treatment in 26 consecutive patients with BCG-refractory HG NMIBC at three years follow-up, demonstrated DFSs of 75%, 71.4%, 50% and 25%, for Ta G3, T1 G3, CIS, Ta/T1 G3 + CIS, respectively”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.2-3"></a>

### Approval status: valrubicin approved, other intravesical chemotherapy used off-label

> “Other intravesical chemotherapies commonly used off-label include gemcitabine, mitomycin C, and the doublet of gemcitabine and docetaxel.”

Source: [Colbert et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11961324/)

> “For over two decades, valrubicin was the only United States Food and Drug Administration (FDA) approved intravesical treatment for patients with BCG‐unresponsive carcinoma in situ (CIS) despite disease‐free rates of only 10% at 1 year following treatment”
> “Other options include non‐FDA approved therapies such as sequential intravesical gemcitabine and docetaxel”
> “which is supported by retrospective evidence only and no prospective clinical trials.”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

<a id="topic-2.2.2.1.2-4"></a>

### Valrubicin: labeled indication, dosing, and administration

> “VALSTAR is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.”
> “VALSTAR is recommended at a dose of 800 mg administered intravesically once a week for six weeks.”
> “Insert a urethral catheter into the patient's bladder under aseptic conditions, drain the bladder, and instill the diluted 75 mL VALSTAR solution slowly via gravity flow over a period of several minutes.”
> “Withdraw the catheter and retain VALSTAR in the bladder for two hours before voiding.”

Source: [Valstar prescribing information (2016)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020892s019lbl.pdf)

<a id="topic-2.2.2.1.2-5"></a>

### Valrubicin: efficacy in BCG-refractory carcinoma in situ

> “In the 90 study patients with BCG-refractory carcinoma in situ (CIS), 70% had received at least 2 courses of BCG and 30% had received one course of BCG and at least one additional course of treatment with another agent(s) - e.g., mitomycin, thiotepa, or interferon.”
> “After intravesical administration of VALSTAR, 16 patients (18%) had a complete response documented by bladder biopsies and cytology at 6 months following initiation of therapy.”
> “Median duration of response from start of treatment varied according to the method of analysis (13.5 months if measured to last bladder biopsy without tumor and 21 months if measured until time of documented recurrence).”

Source: [Valstar prescribing information (2016)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020892s019lbl.pdf)

<a id="topic-2.2.2.1.2-6"></a>

### Valrubicin: safety and the risk of delayed cystectomy

> “Approximately 84% of patients who received intravesical VALSTAR in clinical studies experienced local adverse reactions.”
> “The local adverse reactions associated with VALSTAR usually occur during or shortly after instillation and resolve within 1 to 7 days after the instillate is removed from the bladder.”
> “Delaying cystectomy can lead to development of metastatic bladder cancer, which is lethal.”
> “If there is not a complete response of CIS to treatment after 3 months or if CIS recurs, reconsider cystectomy.”

Source: [Valstar prescribing information (2016)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020892s019lbl.pdf)

<a id="topic-2.2.2.1.2-7"></a>

### Sequential gemcitabine and docetaxel: multi-institution retrospective cohort after BCG

> “Overall 276 patients (median age 73 years, median followup 22.9 months) received treatment. Nine patients were unable to tolerate a full induction course. One and 2-year recurrence-free survival rates were 60% and 46%, and high grade recurrence-free survival rates were 65% and 52%, respectively.”
> “Forty-three patients (15.6%) went on to cystectomy (median 11.3 months from induction), of whom 11 (4.0%) had progression to muscle invasion.”

Source: [Steinberg et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31821066/)

<a id="topic-2.2.2.1.2-8"></a>

### Sequential gemcitabine and docetaxel: long-term single-institution follow-up after BCG failure

> “Median follow-up was 49 months. Median age was 73 years, and 71% of the cohort had CIS containing disease. Thirty five percent of the cohort had BCG-unresponsive disease. Complete response at 3-month surveillance was 74% and median duration of response was 25 months. At 1, 2, and 5 years, HG-RFS was 60%, 50%, and 30%, respectively. HG-RFS was similar among BCG-unresponsive patients and the overall cohort.”
> “Five-year PFS, CFS, CSS, and OS were 82%, 75%, 91%, and 64%, respectively.”

Source: [Chevuru et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36456454/)

<a id="topic-2.2.2.1.2-9"></a>

### Sequential gemcitabine and docetaxel compared with additional BCG in BCG-unresponsive disease

> “Of 299 total patients, 204 underwent additional BCG treatment at the time of BCG unresponsiveness and 95 underwent gem/doce treatment. Rates of PFS (HR 2.6, 95% confidence interval [CI] 1.1-5.0, p = 0.03), CFS (HR 2.0, 95% CI 1.2-3.4, p = 0.01), and CSS (HR 3.7, 95% CI 1.1-12.3, p=0.03) were higher in patients receiving gem/doce. HGRFS, MFS, and OS were similar between both groups.”

Source: [Taylor et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/39694798/)

<a id="topic-2.2.2.1.2-10"></a>

### Sequential gemcitabine and docetaxel: prospective two-institution cohort in BCG-unresponsive disease

> “Sixty-three patients were included. The median follow-up was 14 mo (interquartile range = 8-27). HGRFS rates at 3 and 12 mo were 88.8% (95% confidence interval [CI] = 81.3-97.0) and 68.1% (95% CI = 56.6-81.8), respectively.”
> “Eight patients (12.7%) underwent radical cystectomy and six patients (9.5%) experienced disease progression. Twenty patients (31.7%) experienced mild irritative symptoms and no grade 3 or 4 adverse events were reported.”

Source: [Tan et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42869744/)

<a id="topic-2.2.2.1.2-11"></a>

### Gemcitabine alone compared with sequential gemcitabine and docetaxel: regimens and outcomes

> “Patients received 2 g of gemcitabine in 100 mL of saline, instilled into the bladder via a catheter for a minimum of 60 minutes once weekly for 6 weeks.”
> “Patients received 1 g of gemcitabine in 50 mL of saline, instilled via catheter for 60 to 90 minutes. The bladder was then drained, and 37.5 mg of docetaxel in 50 mL of saline was instilled via a catheter for 60 to 120 minutes. This treatment sequence was administered weekly for 6 weeks.”
> “Median HGRFS was similar between groups (gemcitabine: 22.6 months; Gem/Doce: 19.5 months [P=.25]). Among patients with BCG-unresponsive carcinoma in situ (n=49), median HGRFS was comparable (gemcitabine: 12.2 months; Gem/Doce: 7.6 months [P=.12]).”
> “Low-grade adverse events were common (gemcitabine: 63%; Gem/Doce: 55% [P=.19]), but grade ≥3 adverse events were rare (2.3% vs 2.4%).”
> “Sequential Gem/Doce also poses logistical barriers, including extended chair time, sequential instillation, staffing demands, and reimbursement issues, which may limit its adoption, especially in community settings.”

Source: [Moyer et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13360992/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
